Endpoints News

Post-Hoc Live

News EN ↓ 55 episodios

Post-Hoc Live is an extension of Endpoints' analysis newsletter Post-Hoc — but streamed live on YouTube then brought to you here. Our reporters spend every day texting and calling sources, reading executive orders, and talking to each other in Slack. We're bringing that analysis that happens behind the scenes directly to you, and letting you in on some of our up-to-the-moment conversations. Subscribe to Endpoints and the Post-Hoc newsletter here: https://profile.endpoints.news/create-account. Send us an email at: posthoclive@endpointsnews.com

No dejes de visitar la web del podcast y apoyar a su creador: podcasters.spotify.com

Autor

Endpoints News

Categoría

News

Web del podcast

podcasters.spotify.com

Último episodio

4 de nov. de 2026

¿Dónde escuchar?

Podcasts en la app Replaio Radio Muy pronto

Los podcasts llegarán muy pronto a la app. Instálala ahora y sé el primero en descubrir una forma totalmente nueva de vivir los podcasts

Descárgala en Google Play Instálala gratis Android casi 10 M de descargas · valoración de 4,7+ iOS muy pronto

Episodios

Is biotech sentiment as bad as it seems? 12.06.2025

For the next Post-Hoc live, I'll be joined by Endpoints Founding Editor John Carroll to talk about his twice-a-year sentiment survey of biotech and pharma execs. The results aren't pretty, and John will put them into perspective against more than half a decade of checking the industry's pulse. We'll also be joined by Senior Reporter Kyle LaHucik, who covers public and private deals...

"Most Favored Nation": The White House plan to cut drug prices 12.06.2025

Today, Drew Armstrong is joined by Nick Shipley, the former top lobbyist for the biotech industry, to break down President Trump's "most favored nation" executive order on drug pricing. We’ll talk about what the White House wants, how it could implement those plans, and how the industry and investors are reacting.

What will Vinay Prasad's CBER look like? 12.06.2025

Today, we'll be talking about the news that Vinay Prasad will join FDA as the next director of the Center for Biologics and Research. We'll talk about his past critiques of the agency, his disagreements with former director Peter Marks, and how is tenure might affect vaccine policy, gene therapies, and rare disease companies. I’ll be joined by our senior editor Zach Brennan, who has known...

How pharma is reacting to ‘Liberation Day’ 12.06.2025

We recorded this on April 30, four weeks after Trump’s Liberation Day, when he announced broad tariffs on just about every country on earth, set off chaos in the stock and bond markets, walked some of those tariffs back, and in general upset the world economic order.  If you’ve been reading the news, you know all of that. And if you work in the drug industry, then you’ve been watching and waiting...

Trailer 11.06.2025

This semi-regular series is an extension of out analysis newsletter Post-Hoc. Our reporters spend every day texting and calling sources, reading executive orders, and talking to each other in Slack. We wanted to bring some of that analysis that happens behind the scenes directly to you. We fire Post-Hoc live up in response to major news, at the end of news-y weeks, and to talk to experts about tre...

Escucha el podcast Post-Hoc Live en Replaio

Radio y podcasts en una sola app - gratis y sin registro. Instálala hoy y no te pierdas el estreno

Descárgala en Google Play

Replaio no es editor de podcasts; los nombres de los programas, las portadas y el audio pertenecen a sus autores y se distribuyen a través de canales RSS públicos